News

 

In the evolving landscape of global healthcare, Chinese biopharmaceutical companies are increasingly setting their sights on international expansion as a pivotal strategy for enhancing revenue, competitive edge, and brand value. This pursuit of globalization is likened to navigating a vast ocean, often filled with opportunities and challenges. The methods employed by these enterprises range from establishing manufacturing plants and research institutions overseas, to engaging in technology transfers and obtaining international certifications, which collectively enrich their participation in the global market. The ultimate goal is to optimize resource allocation and continually elevate their capabilities for international innovation.

At the forefront of addressing the complexities of global expansion, a significant question confronts China's biopharmaceutical industry: how do they secure a decisive advantage amidst the waves of internationalization, and thus seek new growth avenues?

Recent discussions at the 2024 Changping Pharmaceutical Health Financial Investment Innovation Forum, featuring luminaries such as Peng Huanhuan, Vice President and General Manager of the Chinese Division of BGI Genomics, Wang Junfeng, Co-Chief Investment Officer and Managing Director of Junlian Capital, and Wu Xiaobin, Global President and COO of BeiGene, provided illuminating insights into the pathways to international collaboration for pharmaceutical enterprises. Their rich perspectives underscore the blend of strategies necessary for success in the evolving landscape of healthcare.

Advertisement

The duality of opportunities and risks is an inherent theme in the journey of internationalization. Reflecting upon the last two decades, the transformation of Chinese healthcare from sheer volume to value is truly remarkable. The industry has ascended from targeting lower-tier markets to addressing premium segments. Products have transitioned from low-quality offerings to those with high added value, and the industrial framework has shifted towards a technology-led model. However, this transition is accompanied by both opportunities and significant risks.

From an opportunity standpoint, the allure of the European and American markets is undeniable, primarily due to their vast scale and lucrative pricing. Dr. Wu Xiaobin cited the case of BeiGene's groundbreaking small molecule Bruton’s tyrosine kinase (BTK) inhibitor, Zymew (zanubrutinib), which achieved global sales of $690 million in its recent quarterly report, highlighting extraordinary growth rates in the US and Europe. This exemplifies the significant commercial potential these markets hold for healthcare products.

Simultaneously, emerging markets, especially in developing regions like Southeast Asia, are gaining prominence. Here, the healthcare landscape mirrors that of China during the era represented in the film "Dying to Survive," where innovative drugs are sparse, and the high prices of Western pharmaceuticals deter accessibility. Chinese innovations, bolstered by affordability and practicality, are perfectly positioned to meet these fresh demands. BeiGene has embarked on strategic explorations in Southeast Asia, particularly in RCEP countries, amassing invaluable experiences that highlight the charm and value of these new markets.

Yet, the path of internationalization is fraught with obstacles and challenges. Political tensions, such as the shifting dynamics in US-China relations, have hindered the expansion efforts of companies like BGI Genomics in the US market.

Dr. Wu advocates a nuanced approach to market entry, suggesting, "For high-quality products, build your own teams, while for more standard products, collaborate with partners. If promising products show efficacy, it makes sense to establish a dedicated international team." This strategic blend is crucial as companies navigate the complexities of international markets.

The current reality indicates a tightening financial environment, compelling firms to exercise greater prudence with their capital. Regulatory hurdles vary wildly across countries, mandating that firms entering regions like Southeast Asia not only grapple with maintaining production quality but also effectively implement local commercialization strategies—each step fraught with challenges.

As companies like BeiGene have embarked on international ventures, they have accrued valuable strategies and experiences. Wu Xiaobin elaborated on their approach: leveraging visionary leadership from their co-founders and piloting global strategies early on. This foresight laid a robust foundation for subsequent global clinical trials and market registrations. Their pioneering efforts, although ahead of their time and met with skepticism, have proven fortuitous. In contrast, several domestic competitors faced setbacks when their clinical data remained confined to China, limiting their entry into the US market.

Moreover, BeiGene’s innovative approach in team-building has significantly contributed to its commercialization successes in Europe, where they directly recruited local talent to form teams adept in regional regulations and market dynamics. This strategy allowed for rapid and accurate market penetration, garnering customer trust and achieving noteworthy product performance. The success of this approach has set a benchmark within the industry, encouraging similar practices across various firms.

Recognizing the operational excellence demonstrated by international heavyweights, Wu noted, “The meticulous approaches international corporations take in research and compliance offer crucial lessons. For instance, when compliance issues arise, even without quality concerns, they do not hesitate to halt production and recall products, showcasing an unwavering commitment to standards.”

Peng Huanhuan shared insights from BGI's journey, which began with its participation in the Human Genome Project. This collaboration with nations like the US and the UK established a strong footing in genomic research and technology. BGI's achievements include sequencing the first Asian human genome and spearheading the Global 1000 Genomes Project, cementing its role in genomic innovation.

Throughout its developmental trajectory, BGI recognized the paramount importance of self-sustainability in core technologies. In addressing technological blockades from overseas entities, the company made a strategic acquisition in 2013 by purchasing a US publicly listed company, effectively gaining control over critical intellectual properties and R&D capabilities.

In its international market strategy, BGI has adopted varied approaches tailored to specific regions. While aiming for sustained presence in the US and European markets—accounting for nearly three-quarters of its business—it has garnered ecological partners to establish global production and R&D bases. In contrast, the Asia-Pacific initiatives focus on affordability and suitability for local research institutions and the public.

BGI also emphasizes localization, striking a balance between deploying core team members and integrating local execution teams to optimize market outreach and understanding of regional regulatory frameworks.

Junlian Capital, as articulated by Wang Junfeng, tapped into overseas investments a decade ago, initially focusing on Western markets. However, through reflective practices, they realized the essential synergy between global innovative technologies and China’s domestic advantages for maximizing comparative gains. Consequently, in 2020, Junlian Capital shifted its focus to Southeast Asia, driven by the substantial price disparities for medical products like PD-1, which present remarkable profit margins for Chinese healthcare firms.

Despite the allure of Southeast Asia, Wang underscores that navigating this market presents its own challenges. "Maintaining quality consistent with local production standards necessitates careful selection of raw materials and adherence to rigorous production processes," he said. Moreover, the lack of mature marketing frameworks in Southeast Asia calls for a localized adaptation of advanced techniques from both domestic and international coined approaches—an amalgamation of local talent solutions and expertise from mature market professionals, forming a bridge to advance technological adoption.

In the context of global healthcare, optimizing supply chains has emerged as a crucial determinant of international competitive strength. With globalization accelerating, the global supply chains are increasingly interconnected. For pharmaceutical companies, this dual-focus strategy centers on upgrading domestic supplier capabilities, while also diversifying raw material sources internationally, mitigating potential geopolitical risks.

According to Dr. Wu, key to brand establishment in the healthcare domain is rooted in unwavering product quality and empirical clinical data. "When marketed products exhibit significant clinical efficacy and improve patient outcomes, they naturally generate positive reputation and sales," he remarked.

Striking a balance between immediate market expansion and long-term brand integrity calls for sharp insights and decisive tactics. Companies need the agility to tweak strategies based on market conditions and regional dynamics—expanding in thriving markets while exercising caution in less favorable environments.

Moreover, every entity must embrace the unique characteristics of various markets, adapting their strategies accordingly. The developed markets have heightened expectations for quality and precision, while regions like Asia-Pacific and Africa prioritize cost-effectiveness. The need for localized research becomes critical in tailoring products that resonate with consumers' specific needs, regulatory requirements, and cultural contexts.

Ultimately, perseverance in international ventures is vital as fruitful market penetration typically requires time and sustained commitment.

In summary, as healthcare enterprises embark on their international collaborative journeys, they must navigate the intertwined realities of opportunity and challenge. The experiences and strategies of BeiGene, BGI, and Junlian Capital exemplify how precision in recognizing opportunities, courageously addressing challenges, and crafting individualized strategies can foster a resilient and sustainable competitive ecosystem in the international arena. Drawing on Wang Junfeng’s insights, a robust international strategy encompasses comprehensive preparation, including technological, product, and talent readiness, emphasizing a collaborative, localized approach. There is firm belief in the capacity of Chinese medical enterprises to thrive globally, yet each firm must design unique strategies reflective of their distinct products and market readiness to achieve meaningful international milestones.